We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
WTC
226
WhitTier Trust Company
Nevada
$1K +$607 +4 New
AssetMark Inc
227
AssetMark Inc
California
$1K +$759 +5 New
SFSIG
228
San Francisco Sentry Investment Group
California
$1K +$1.21K +8 New
KPW
229
Kore Private Wealth
New York
$1K +$1.52K +10 New
CFGS
230
Concourse Financial Group Securities
Alabama
$1K +$1.97K +13 New
Schroder Investment Management Group
231
Schroder Investment Management Group
United Kingdom
$394 +$427K +2,815 New
GT
232
Glenmede Trust
Pennsylvania
$159 +$15.9K +105 +10%
O
233
OrbiMed
New York
-$56.4M -330,000 Closed
HIM
234
Hillhouse Investment Management
Cayman Islands
-$22.4M -131,300 Closed
Renaissance Technologies
235
Renaissance Technologies
New York
-$22M -128,800 Closed
SCM
236
Suffolk Capital Management
New York
-$7.07M -41,399 Closed
Adage Capital Partners
237
Adage Capital Partners
Massachusetts
-$5.98M -35,000 Closed
CM
238
Castleark Management
Illinois
-$5.54M -32,445 Closed
EI
239
EAM Investors
California
-$2.32M -13,593 Closed
First Trust Advisors
240
First Trust Advisors
Illinois
-$1.04M -6,092 Closed
Hudson Bay Capital Management
241
Hudson Bay Capital Management
Connecticut
-$854K -5,000 Closed
JMPWA
242
JP Morgan Private Wealth Advisors
California
-$742K -4,343 Closed
SAM
243
Sectoral Asset Management
Quebec, Canada
-$546K -3,195 Closed
Teacher Retirement System of Texas
244
Teacher Retirement System of Texas
Texas
-$453K -2,650 Closed
Balyasny Asset Management
245
Balyasny Asset Management
Illinois
-$351K -2,055 Closed
ECM
246
Element Capital Management
New York
-$344K -2,012 Closed
Pacer Advisors
247
Pacer Advisors
Pennsylvania
-$255K -1,492 Closed
LPL Financial
248
LPL Financial
California
-$244K -1,429 Closed
Jacobs Levy Equity Management
249
Jacobs Levy Equity Management
New Jersey
-$232K -1,360 Closed
TSS
250
Two Sigma Securities
New York
-$213K -1,247 Closed

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.